Senesco Technologies (SNT) Signs a Supply Agreement for Polyplus-transfection's Delivery System

July 3, 2008 8:46 AM EDT

Senesco Technologies, Inc. (AMEX: SNT) has contracted with Polyplus-transfection (Illkirch, France) to supply Polyplus's "in vivo-jetPEI" for systemic delivery of Senesco's combination therapy of siRNA against Factor 5A and a plasmid of the Factor 5A gene.

Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid delivered with "in vivo-jetPEI" against subcutaneous multiple myeloma tumors in immunodeficient mice.

"This supply agreement will help Senesco move toward the necessary preclinical toxicology study and ultimately the planned clinical trial targeting multiple myeloma," commented Bruce Galton, Senesco's President and CEO. "Polyplus' PEI technology is already being used in clinical oncology trials by other companies and we look forward to working with them and using their technology to deliver our Factor 5A technology."[SM]

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?